Europe and Middle East Spinal Cord Stimulation Devices for Chronic Pain Market is expected to reach US$ 1,573.67 million by 2030

Publisher: The Insight Partners

According to our new research study on “Europe and Middle East Spinal Cord Stimulation Devices for Chronic Pain Market Forecast to 2030 – Regional Analysis – by Product Type, Application, and End User,” the Europe and Middle East spinal cord stimulation devices for chronic pain market size is expected to grow from US$ 892.66 million in 2022 to US$ 1,573.67 million by 2030; it is estimated to register a CAGR of 7.3% during 2022–2030.

Key factors driving the Europe and Middle East spinal cord stimulation devices for chronic pain market growth include the rising number of spinal cord injuries and availability of innovative treatments in the European Union (EU). However, product recalls hinder the market growth.

Availability of Innovative Treatments in European Union

According to a report published by the European Commission, SCI is responsible for causing motor impairment with sensation loss, chronic pain, and other locomotor dysfunction. Therefore, in the European Union (EU), several rehabilitation programs are being conducted for patients living with SCIs. The SPINAL CORD REPAIR Project (SCRP) is one such example that is a multidisciplinary collaboration among EU scientists. The SCRP is responsible for restoring physical movements such as motor function or movement after SCIs. Under this program, an experimental setup—MotoRater—was developed and trademarked for the standardized testing for locomotion movements among rodents as a part of clinical testing. These rodents were utilized to identify and characterize the cellular properties of excitatory central pattern generator (CPG) neurons such as EphA4, which are responsible for locomotion. CPG is a neural circuit in the spinal cord that stimulates rhythmic movements from the interplay between CPG neurons and their synaptic interactions. The clinical research results were presented through meetings and congresses; patents were filed and published. Therefore, the ongoing innovations in the treatments of spinal cord disorders in the EU help improve the mobility and quality of life for millions suffering from SCI.

Several biopharma companies are developing innovative products to treat SCIs. BioArctic, a Swedish biopharma company, is dedicated to developing treatments for central nervous system (CNS) disorders. For instance, in February 2019, BioArctic developed "SC0806," a biodegradable medical device that is surgically implanted into an injured spinal cord. Upon the implantation of "SCO806," the device guides nerve fibers across the injured area in spinal cord. Such innovative product launches by the competitive players to treat SCI fuel the growth of the spinal cord stimulation devices for chronic pain market in Europe and the Middle East.

Market Opportunity

Rehabilitation and Specialized Centers Providing Effective Treatment for Spinal Cord Injuries

According to a report by the NIH, specialized centers of care for SCI were first established in England with an objective to improve the care and neurological recovery of patients. SCI tertiary care centers are developed to improve clinical outcomes and neurological recovery among patients suffering from acute SCIs. Additionally, the Spinal Cord Injury Center at Heidelberg University Hospital in Germany is the only academic center dedicated to the treatment and research of SCIs. The staff at Heidelberg University Hospital, including ~145 staff members, provides treatment to ~1,500 patients suffering from acute or chronic spinal cord injuries annually, among which 1,000 receive outpatient care.

Spinal cord stimulation devices are highly adopted in rehabilitation centers. A treatment method based on these devices supports patients physically and psychologically to maximize their neurological recovery and general health in a short time. The Walk Again Center based in Berlin is one such example of a rehabilitation center to treat neurological conditions. This rehab center employs both medicine and technology to treat SCIs. It uses innovative medical procedures, including structural and neural neuroplasticity, where doctors provide therapy to patients suffering from brain damage. Therefore, advanced rehab centers and specialized centers provide growth opportunities to the Europe and the Middle East spinal cord stimulation devices for chronic pain market.

Boston Scientific Corp, Abbott Laboratories, Medtronic Plc, Curonix LLC, Biotronik SE & Co KG, Nevro Corp, Nalu Medical Inc, Cirtec Medical Corp, and Synapse Biomedical Inc.are among the leading companies operating in the Europe and Middle East spinal cord stimulation devices for chronic pain market.   

Strategic Insights

• In December 2022, The Eterna spinal cord stimulation (SCS) system from Abbott Laboratories is now available for the treatment of chronic pain. Abbott's low-dose BurstDR stimulation, a patented low-dose SCS waveform technology with the greatest level of clinical evidence, has been approved by the FDA, the firm reported. Additionally, it has been demonstrated that the technique reduces pain 23% more than conventional waveform technology methods.
• In August 2023, Medtronic plc announced that it received CE (Conformité Européenne) Mark approval for its Inceptiv. The device is a closed-loop rechargeable spinal cord stimulator (SCS) and is the company's first SCS device to offer a closed-loop feature. Inceptive is equipped with technology that can sense each patient's unique biological signals, adjust stimulation as per the patient's moment, and offer harmonized therapy with the motions of daily life.

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com